R
Rectify Pharmaceuticals
Breakthrough ABC transporter platform enabling rapid discovery of small molecule therapies for liver, biliary, eye, CNS, and cardiometabolic diseases
About Rectify Pharmaceuticals
Rectify Pharma is a biotech startup that specializes in the development of small molecule therapies. These therapies are designed to restore and enhance the function of ATP-binding cassette (ABC) transporters, a type of protein that plays a crucial role in the body by transporting various substances across cell membranes. The company's innovative product platform is aimed at discovering new treatments for a variety of diseases, including those affecting the liver, biliary system, eyes, central nervous system, and cardiometabolic health.
Rectify Pharma's primary market is the healthcare sector, specifically targeting both rare and common diseases. Their business model revolves around the research and development of first-in-class therapies, which they aim to commercialize through partnerships or sales to larger pharmaceutical companies.
The company is led by Rajesh Devraj, Ph.D., a seasoned biotech executive with a track record of building successful companies. His extensive experience in the field, coupled with a strong leadership team, positions Rectify Pharma well for future growth and innovation.
In summary, Rectify Pharma is a promising biotech startup that leverages cutting-edge science to develop novel therapies for a range of diseases. Their focus on ABC transporter function could potentially open up new avenues for treatment, making them a company to watch in the healthcare sector.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Cambridge, United States
- Employees
- 19
- Open positions
- None listed
- Dealroom signal
- 62.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Disease, Biotech and Pharma, Hard Tech, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Oct 2021 | $100M | $400M | Longwood Fund · Omega Funds · Atlas Venture · Forbion Capital Partners | — |
Growth signals
Latest recorded traffic for Rectify Pharmaceuticals is 2K monthly website visits, up 81.8% over the last three months. Rectify Pharmaceuticals's team grew 5.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Longwood Fund
Atlas Venture
Forbion Capital Partners
Omega Funds
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Rectify Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Rectify Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.